SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2020

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.

Marscha S Holleman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.